Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 4/20 | 0.39 |
| ▸ | GAK | O14976 | 3/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051850 | 1.00 | LRRK2 (0.40) | LRRK2FFAR2GAKPDE3BPDE3A | |
| SCHEMBL29742367 | 0.81 | — | — | |
| SCHEMBL20189905 | 0.81 | — | — | |
| SCHEMBL30051424 | 0.79 | MAPT (0.44) | LRRK2FFAR2PDE3BPDE3AMAPT | |
| SCHEMBL20189764 | 0.79 | MAPT (0.44) | LRRK2FFAR2PDE3BPDE3AMAPT | |
| SCHEMBL16702620 | 0.78 | LGMN (0.50) | MAP3K12MAPT | |
| SCHEMBL20199859 | 0.77 | KDM4E (0.58) | LRRK2MAPT | |
| SCHEMBL23375904 | 0.77 | PIK3CA (0.46) | LRRK2FFAR2GAKMAP3K12ATR | |
| SCHEMBL31570672 | 0.76 | LRRK2 (0.43) | LRRK2FFAR2 | |
| SCHEMBL30051838 | 0.75 | GSK3A (0.47) | LRRK2FFAR2GAKATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3544980-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276463-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | LRRK2 94/4885FFAR2 3543/4885GAK 884/4885 |
| US-10774086-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | LRRK2 94/4885FFAR2 3543/4885GAK 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.